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Multiple System Atrophy (MSA) is a neurodegenerative disease characterized by the
accumulation of misfolded α-synuclein (α-Syn) in oligodendrocytes of the central nervous
system (CNS). A previous study in our lab used Affymetrix DNA microarray analysis to show
the downregulation of various mitochondrial related genes, as well as the upregulation of genes
involved in inflammatory/immune responses in MSA brain tissue. Therefore, it is hypothesized
that an increased presence of immune proteins exists in the MSA brain accompanied by glial cell
pathology including decreases in cell metabolism and cell viability. This study uses
immunohistochemistry (IHC) to show the increased presence of CD68 and CD33, two
microglia/macrophage associated proteins, and a greater number of CD8α positive lymphocytes
in the pontocerebellar tracts of MSA pons. This suggests an immune response mediated by
microglia and/or macrophage cells, as well as cytotoxic T cells in an area of the brain plagued by
α-Syn. In addition to increased immune activity, glial cells are directly affected in MSA. This
study uses a cell culture model of MSA comprised of C6 glioma cells treated with exogenous αSyn. Cells exhibited less dehydrogenase activity accompanied by decreases in total cell number
without significant loss of cell viability, decreased mitochondrial membrane potential was also
detected. These data suggest decreases in cell metabolism via mitochondrial dysfunction and cell
loss, potentially from reduced proliferation, contribute to the pathogenesis of MSA.
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CHAPTER I

INTRODUCTION

Overview of Multiple System Atrophy
Multiple System Atrophy (MSA) is an adult-onset progressive neurodegenerative disease
classified as an alpha-synucleinopathy. Alpha-synucleinopathies are characterized by the
accumulation of the misfolded protein, alpha-synuclein (α-Syn), in brain cells (MartÌ et al.,
2003). In MSA, α-Syn primarily accumulates in oligodendrocytes (Spillantini and Goedert,
2000). The term, Multiple System Atrophy, was first introduced in 1969 by Graham and
Oppenheimer (Graham and Oppenheimer, 1969) to describe what was once thought to be several
different conditions: idiopathic orthostatic hypotension, olivopontocerebellar atrophy (OPCA),
striagtonigral degeneration (SND), and Shy-Drager syndrome (SDS) (Graham and Oppenheimer,
1969; Quinn, 1989; Wenning et al., 2004). Today, MSA is classified as two clinical variants
based on the predominating symptoms, MSA-P (previously described as SND) and MSA-C
(previously described as OPCA) (Gilman et al., 1998). While many patients will develop a
combination of symptoms which may change over time, these two clinical types refer to
symptoms that are exhibited at the time of patient assessment (Gilman et al., 2008). MSA-P is
predominated by parkinsonism; this involves postural instability, tremor, akinesia, and rigidity
(Gilman et al., 1998; Gilman et al., 2008). Pathology in MSA-P primarily occurs in the striatum
and substantia nigra (Wenning et al., 2002; Wenning et al., 2004). MSA-C consists of olivo
pontocerebellar pathology predominated by cerebellar ataxia (Gilman et al., 1998; Gilman et al.,
2008). Cerebellar dysarthia, as well as gait and limb ataxia are other clinical features of MSA-C
1

(Köllensperger et al., 2010; Gilman et al., 2008; Wenning et al., 1997; Wenning et al., 1994).
The clinical symptoms in MSA can be generally divided into three categories:
parkinsonism, cerebellar ataxia, and failure of the autonomic nervous system (Quinn et al., 1989;
Gilman et al., 1998; Gilman et al., 2008). Regardless of the MSA subtype, the majority of MSA
patients will develop parkinsonism (Gilman et al., 1998; Köllensperger et al., 2010). Symptoms
of parkinsonism in MSA include bradykinesia, postural instability, tremor, akinesia, rigidity, and
levodopa unresponsiveness (Gilman et al., 1998; Gilman et al., 2008, Köllensperger et al., 2010;
Wenning et al., 1997; Wenning et al., 1994). Autonomic dysfunction in MSA commonly
presents as urinary incontinence, erectile dysfunction in males, and orthostatic hypotension
(Wenning et al., 1997; Wenning et al., 1994). Other symptoms include constipation, urinary
retention, nocturnal hypertension, and sleep disorders (Vetrugno et al., 2004; Wenning et al.,
1997; Wenning et al., 1994). Cerebellar dysfunction occurs in more than 36% of MSA patients;
the most common symptom is gait ataxia often accompanied by limb ataxia and sometimes
impaired speech and oculomotor abnormalities of cerebellar origin (Testa et al. 2001;
Köllensperger et al., 2010; Wenning et al., 1997).
Like many neurodegenerative diseases, MSA is considered a sporadic disease, the
etiology of the disease unknown (Gilman et al., 1998; Gilman et al., 2008; Mitsui and Tsuji,
2014). While the primary cause of MSA is not known, some associated environmental risks have
been identified; these include exposure to metal dusts and fumes, plastic monomers and
additives, and pesticides (Nee et al., 1991). In addition to environmental risks, there may also be
genetic risks. One study identified potential genetic risk factors associated with single nucleotide
polymorphisms (SNPs) in the SNCA locus (Scholz et al., 2009). In another study, a specific
mutation in COQ2 was found in Japanese participants and was associated with increased risk of
2

sporadic MSA (Multiple-System Atrophy Research Collaboration, 2013).
By definition, MSA is considered a rare or orphan disease, affecting less than 200,000
nationwide (Aronson, 2006). Results from five studies show the crude prevalence of MSA
ranging from 1.9 to 4.9 cases per 100,000 persons (Bjornsdottir et al., 2012; Bower et al., 1997;
Chiò et al., 1998; Chrysostome et al., 2004; Schrag et al., 1999); and the incidence was found to
be 0.6 cases per 100,000 persons (Bjornsdottir et al., 2012; Bower et al., 1997). In populations
older than 50 years, the incidence rate increased to 3 cases per 100,000 persons per year
(Stefanova et al., 2009; Wenning et al., 2004). While these studies provide an estimated number
of people affected by MSA, it is probable that MSA is often undiagnosed and/or misdiagnosed.
Depending on the variant of MSA, MSA-P or MSA-C, macroscopic pathology might be
more severe in either the striatonigral or olivopontocerebellar regions, respectively (Ahmed et
al., 2012). The brain of MSA patients displays atrophy in the pons, cerebellum, putamen, middle
cerebellar peduncle (Gilman et al., 1998; Gilman et al., 2008; Ahmed et al., 2012), and less
frequently cortical atrophy (Rehman, 2001). Atrophy of the pons can be an important diagnostic
tool because this does not occur in Parkinson’s disease (PD) (Dickson, 2012). In MSA-P, the
putamen is atrophied with dark discoloration and the substantia nigra and locus ceruleus appear
pale (Ahmed et al., 2012, Wenning et al., 2005). In patients with MSA-C, a size reduction of the
pons can be observed and discoloration can be seen in the white matter of the cerebellum
(Ahmed et al., 2012). Patients with MSA-C also exhibit loss of Purkinje cells and olivopontine
nuclei (Wenning et al., 1996). While atrophy is observed in both types of MSA, the overall
weight of the brain is typically not affected; this differs from Alzheimer’s disease (AD) in which
decreased brain weight is a pathological feature (Ahmed et al., 2012; Perl, 2010). The
microscopic changes observed in MSA involves gliosis, cell loss, and loss of myelin throughout
3

multiple brain areas, which include but are not limited to the cerebellum, pons, and substantia
nigra (Matsuo et al., 1998; Ozawa et al., 2004; Wenning et al., 1994). As previously mentioned,
a major component of inclusion bodies in MSA is the protein α-Syn, a neuronal protein that also
contributes to pathology in other synucleinopathies, including Parkinson’s disease (PD), as well
as dementia with Lewy bodies (Baba et al., 1998; Spillantini et al., 1997). Alpha-synuclein is a
140 amino-acid cytoplasmic protein, primarily found in the presynaptic terminals of neurons in
the CNS (Davidson et al., 1998). While limited information is available regarding the function of
α-Syn, it is thought to play a role in neurotransmitter release and promotion of soluble NSF
attachment protein receptor (SNARE)-complex assembly (Burré et al., 2010; Burré, 2015). It has
also been shown that α-Syn interacts with the mitochondrial membrane (Chinta et al., 2010;
Shavali et al., 2008).
The histological hallmark of MSA is the presence of α-Syn positive, argyrophilic glial
cytoplasmic inclusions (GCIs) in oligodendrocytes (Burn and Jaros, 2001; Trojanowski and
Revesz, 2007). In fact, a definite diagnosis of MSA involves the identification of α-Syn
containing GCIs in postmortem brain tissue (Trojanowski and Revesz, 2007). Normally, α-Syn
mRNA is not found in human oligodendrocytes and therefore current research suggests that
exogenous α-Syn originating from neurons is internalized by oligodendrocytes (Reyes et al.,
2014). Other than GCIs, inclusions have also been identified in glial nuclei (glial nuclear
inclusions (GNIs)) (Burn and Jaros, 2001), and less frequently in neuronal cytoplasm (neuronal
cytoplasmic inclusions (NCIs)), and neuronal nuclei (neuronal nuclear inclusions (NNIs)) (Burn
and Jaros, 2001; Nishie et al., 2004). NCIs are found in many brain regions including the
pontine and olivary nuclei (Wenning et al., 2005; Nishie et al., 2004). In addition to being the
primary cell affected by α-Syn inclusions, cell death via apoptosis is more prevalent in
4

oligodendrocytes then in neurons, distinguishing MSA from other neurodegenerative diseases
(Probst-Cousin et al., 1998). One study demonstrated elevated levels of an apoptosis suppressor
protein, bcl-2, in GCI containing oligodendrocytes (Probst-Cousin et al., 1998). The increase in
bcl-2 observed in affected oligodendrocytes suggests a final effort to repair the cell and prevent
cell death (Probst-Cousin et al., 1998).
Demyelination is another pathological marker of MSA, occurring in multiple brain
regions (Matsuo et al., 1998; Wong et al., 2014). Myelin is a specialized plasma membrane
produced in oligodendrocytes that insulates axons and allows for saltatory conduction (Aggarwal
et al., 2011). In early stages of MSA, oligodendrocytic changes occur that are associated with the
degradation of myelin (Song et al., 2007). One of these changes is the relocalization of the
oligodendrocytic protein tubulin polymerization promoting protein (TPPP), also called p25α
(Lindersson et al., 2005; Song et al., 2007). In a healthy brain, p25α is a ligand that binds to
myelin basic protein (MBP) in the white matter tracts (Lindersson et al., 2005; Song et al., 2007).
In MSA, p25α relocalizes to the cell body prior to the accumulation of aggregated α-Syn
(Lindersson et al., 2005; Song et al., 2007). The buildup of p25α continues throughout the
accumulation of α-Syn and may promote aggregation; it localizes to α-Syn positive GCIs,
concurrent with degradation of MBP (Lindersson et al., 2005; Song et al., 2007). In addition to
changes in myelin, enlargement of oligodendrocyte cell bodies is also observed in MSA
(Lindersson et al., 2005; Song et al., 2007).
Although not well characterized, inflammation and an elevated immune response are observed in
MSA. Degraded myelin product, cell loss, and gliosis may all be contributing factors to
neuroinflammation in MSA. Previous research has shown upregulation of genes involved in
inflammatory/immune responses present in MSA pons tissue (Langerveld et al., 2007). Both the
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activation of microglia (Ishizawa et al., 2004; Zhang et al., 2005), and release of inflammatory
cytokines from astrocytes can be stimulated by α-Syn and are thought to contribute to
progression of MSA (Lee et al., 2010a, Lee et al., 2010b). Reactive microglia phagocytose
degraded myelin and contribute to further release of inflammatory molecules (Ishizawa et al.,
2004). Cells of the adaptive immune system, such as T cells, may also be involved in MSA,
since they have been implicated in other neurodegenerative diseases (Brochard et al., 2009;
Tzartos et al., 2008).
While neuroinflammation may play an important role in MSA pathogenesis, this may
also be true of mitochondrial dysfunction and oxidative stress (Hsu et al., 2000). Downregulation
of mitochondrial related genes have been demonstrated in the pons of MSA brain tissue
(Langerveld et al., 2007). Overexpression of α-Syn in vitro induces changes in mitochondrion
size and activity associated with mitochondrial dysfunction. In a mouse model of MSA, the
overexpression of α-Syn by oligodendrocytes plus exposure to mitochondrial inhibition by 3nitropropionic acid was shown to induce a full range of MSA symptoms and neuropathology that
includes gliosis, reactive microglia, and cell loss (Stefanova et al., 2005).
Objective of the Current Study
The progression of MSA appears to be related to neuroinflammation associated with the
accumulation of α-Syn in glial cells. Therefore, the objective of this study is to determine if there
is differential expression of three immune proteins, CD8α, CD68, and CD33 in the
pontocerebellar tracts of patients with MSA, an area known to be affected by accumulation of αSyn. Since previous work in the lab demonstrates an increase in genes involved in the
immune/inflammatory response, it is my hypothesis that the presence of these three proteins will
be increased in the MSA pontocerebellar tracts of the pons. Therefore, chapter two discusses
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differences in the immunostaining of two microglia and macrophage markers, CD68 and CD33,
and the cytotoxic T cell marker CD8α, within the pontocerebellar tracts of MSA pons tissue
compared to non-MSA controls. Immunohistochemistry was used to visualize these three
proteins. Following staining, image analysis was used to quantify and compare the stained areas
of CD68 and CD33, and the number of CD8+ lymphocytes in MSA and control pons.
In addition to an inflammatory/immune response, MSA pathogenesis is also associated
with pathological changes in glial cells including mitochondrial dysfunction (Stefanova et al.,
2005), cell death (Probst-Cousin et al., 1998), and changes in morphology (Lindersson et al.,
2005; Song et al., 2007). Thus, this study aims to identify changes in mitochondrial function, cell
viability, and nuclear morphology using C6 glioma cells as a cell culture model of MSA. It is my
hypothesis that C6 cells treated with exogenous α-Syn will exhibit decreases in dehydrogenase
activity along with loss of cell viability. I also hypothesize that treatment with α-Syn causes
changes in nuclear size, as well as decreases in mitochondrial membrane potential associated
with mitochondrial dysfunction. Thus, chapter three describes how cells were cultured and
incubated with exogenous α-Syn to determine various effects on C6 cells. Spectrophotometrical
analysis was used to quantify dehydrogenase activity after the addition of α-Syn into C6 cell
cultures. This was followed by live and dead cell counts, to determine an effect on cell viability.
Additionally, chapter 3 shows how α-Syn leads to a dose-dependent changes in the
mitochondrial membrane potential in C6 cells treated with α-Syn. A nuclear counterstain was
used to visualize the nuclei of C6 cells. Image analysis was used to measure nuclei and show
differences in C6 cell nuclear size following treatment with α-Syn.
The results of this study showed increased presence of innate immune proteins, CD68
and CD33, and increased numbers of CD8α positive lymphocytes within the MSA brain, which
7

is likely associated with α-Syn aggregation. However, the effect of α-Syn is not isolated to the
induction of the immune system, it is also associated with pathological changes in glial cells
(Burn and Jaros, 2001; Probst-Cousin et al., 1998; Lee et al., 2010a; Lee et al., 2010b; Stefanova
et al., 2001; Stefanova et al., 2007; Trojanowski and Revesz, 2007; Zhang et al., 2005). To
demonstrate glial cell pathology, this study used a cell culture model of MSA comprised of C6
glioma cells treated with exogenous α-Syn. After incubation with α-Syn, cells exhibited less
dehydrogenase activity along with decreased mitochondrial membrane potential in a dosedependent manner. These data suggest decreases in cell metabolism via mitochondrial
dysfunction are also contributing to the pathogenesis of MSA. While lowered cell metabolism
was observed, there was no significant loss of cell viability. These data suggest that it may be
possible to reverse the effects of α-Syn in the early stages of disease progression. In addition, a
dose-dependent increase in nuclear size was detected in α-Syn treated cells. This indicates the
formation of α-Syn containing inclusions (Ahmed et al., 2012) which are dependent on α-Syn
concentration. Overall this study presents evidence that MSA may involve innate and adaptive
immune responses accompanied by metabolic dysfunction. This work sets the stage to determine
if anti-inflammatory drugs and or therapeutics to treat metabolic disorder may be used in the
treatment of MSA.
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CHAPTER II

INCREASED PRESENCE OF CD68 AND CD33 AND CD8 POSITIVE LYMPHOCYTES IN
THE PONTOCEREBELLAR TRACTS OF MULTIPLE SYSTEM ATROPHY PONS TISSUE

The Pons in Multiple System Atrophy
As previously discussed in chapter 1, the pons is a major region of the brain that exhibits
abnormalities such as atrophy and cell loss in MSA. High densities of GCIs (Probst-Cousin et al.,
1998), NNIs, and NCIs (Nishie et al., 2004) have been detected in the pons of MSA patients.
GCIs are a pathological hallmark of MSA, and the density of these inclusions appears to
correlate with neuronal cell loss, as well as an inflammatory response (Ozawa et al., 2004;
Stefanova et al., 2007). A previous study in our lab found gene expression changes in the pons of
MSA brain tissue (Langerveld et al., 2007). Genes involved in the regulation of the inflammatory
immune response including ANAX1, IFI16, TNFAIP6, as well as genes encoding complement
components 4a and 4b, were upregulated in the pons (Langerveld et al., 2007). In addition,
immunostaining of the pontocerebellar tracts of the pons showed significantly more α-Syn, (a
main component of GCIs) in MSA patients compared to controls (Langerveld et al., 2007).
These findings suggest that an inflammatory response is present in the pons, and more
specifically in the pontocerebellar tracts of the pons. These previous observations lead us to
further investigate an immune response in the pons of MSA patients.
Anatomy and Function of the Pons
The pons is one of the three major subdivisions of the brainstem. It includes the middle
cerebellar peduncles, a portion of the fourth ventricle, and the basal pons. The pons is located
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ventral to the cerebellum and superior to the medulla. The pons relays information to parts of the
cerebrum, as well as the cerebellum.
The pons consists of multiple structures, which include the corticospinal fibers,
corticopontine fibers, pontocerebellar fibers, and medial lemniscus (Gartner and Patestas, 2009;
Haines, 2012; Naidich et al., 2009; Noback et al., 2005; Vanderah and Gould, 2015). The
corticospinal fibers originate in the motor cortex and terminate on the anterior horn of the spinal
cord (Naidich et al., 2009). In the basal pons, these tracts divide into numerous small clusters. As
these fibers transverse the brainstem, they form collateral fibers to various structures including
the pontine nuclei (Naidich et al., 2009). The corticopontine fibers originate in the cerebral
cortex and enter the pons where they terminate in the pontine nuclei (Noback et al., 2005). The
pontocerebellar fibers are transversely oriented fibers that originate from the pontine nuclei
(Haines, 2012). These fibers run from the pons to form the middle cerebellar peduncle and then
enter the cerebellum where they terminate as mossy fibers in the cerebellar cortex (Vanderah and
Gould, 2015). The medial lemniscus is an ascending bundle of heavily myelinated axons that
project from the contralateral posterior column nuclei and trigeminal sensory nuclei to the
ventral posterolateral nucleus of the thalamus (Vanderah and Gould, 2015). These form the
primary ascending pathway for proprioception and tactile information (Vanderah and Gould,
2015).
Immune Response in the Brain
Almost any pathology in the CNS means the involvement of glial cells. Microglia are the
resident immune cells of the CNS. In a healthy brain, microglia play a role in host defense and
monitor the microenvironment for pathological changes (Kreutzberg, 1996). Resting microglia
rapidly transition from a ramified to an amoeboid morphology when activated (Kreutzberg,
10

1996). Activated microglia are important for removing tissue debris and promoting regeneration
of damaged tissue (Streit, 2002). However, an uncontrolled response leads to the upregulation of
inflammatory cytokines contributing to tissue damage (Kreutzberg, 1996). In addition to
traumatic brain injury, the activation of microglia is also associated with neurodegenerative
diseases including AD, PD, progressive supranuclear palsy (PSP), corticobasal degeneration
(CBD), and MSA (Liu and Hong, 2003; Ishizawa et al., 2004; Stefanova et al., 2007). In MSA, it
is thought that glial cells uptake α-Syn from the extracellular environment (Lee et al., 2010a; Lee
et al., 2010b). The uptake of α-Syn by astrocytic glial cells correlates with inflammation and
activation of the innate immune response. Astrocytes show increased production of inflammatory
cytokines, such as IL-1, IL-6, and TNFα, as well as various chemokines upon exposure to
neuronal α-Syn (Lee et al., 2010a; Lee et al., 2010b). In addition to astrocyte release of
inflammatory molecules, it has also been shown that α-Syn can directly activate microglia in
vitro (Zhang et al., 2005). Toll-like receptors have also been shown to interact with α-Syn
(Fellner et al., 2013). The introduction of α-Syn into TLR4+/+ microglia cultures from the brains
of mice was associated with increased phagocytosis and production of cytokines (Fellner et al.,
2013). One mouse model of MSA showed a correlation between activated microglia and
neuronal cell loss, with a large population of activated microglia in white matter tracts
(Stefanova et al., 2007).
This study further defines the innate immune response in MSA by demonstrating
increased immunostaining of two microglia/macrophage markers, CD68 and CD33, in the
pontocerebellar tracts of MSA pons tissue. CD68 is a transmembrane glycoprotein that is highly
expressed on macrophages, monocytes, and microglia (Chistiakov et al., 2017; O'Reilly et al.,
2007; Walker et al., 2015). While the function of CD68 is not well defined, it is a member of
11

scavenger receptor family, which plays a role in phagocytosis and inflammation (Chistiakov et
al., 2017; Song et al., 2011). While no functional role has been shown, CD68 expression is
associated with inflammation (Chistiakov et al., 2017). In our lab, a preliminary study showed
the upregulation of CD68 in the pons and cerebellar white matter tracts of MSA patients
(Wagner 2013). Like CD68, CD33 (Siglec-3) is an adhesion molecule expressed on cells of
myeloid lineage. It belongs to a group of immunoglobulin-like lectins that mediate sialic-acid
dependent binding to cells. Some functions of CD33 include cell adhesion via binding to highaffinity sialoglycans; it is also involved in inhibition of proliferation, promotion of apoptosis,
modulating cytokine secretion in immune cells, and inhibition of immune cell functions (Crocker
et al., 2007; Jandus et al., 2011; Jiang et al., 2014; Lajaunias et al., 2005; Paul et al., 2000). In the
brain, CD33 is mainly expressed on microglial cells (Jiang et al., 2014).
While multiple studies suggest an innate immune response occurs in the progression of
MSA, the role of the adaptive immune system is less detailed. The pathogenesis of other
neurodegenerative disorders, such as PD and multiple sclerosis (MS) involve the infiltration of
cells associated with the adaptive immune system. The infiltration of CD4+ (helper) T
lymphocytes and CD8+ (cytotoxic) T lymphocytes have been observed in the postmortem brain
tissue of PD patients and in brain tissue of a PD mouse model (Brochard et al., 2009). As for
MS, the production of the pro-inflammatory cytokine, Interleukin 17 (IL-17), has been observed
in CD4+ and CD8+ lymphocytes located within lesions (Tzartos et al., 2008). Interestingly,
CD8+ are the predominating T lymphocytes in MS lesions and appear to have a pathogenic
effect (Babbe et al., 2000; Tsuchida et al. 1994; Skulina et al., 2004). Since the adaptive immune
system is associated with the progression of other neurodegenerative disorders, it may also be a
contributing factor in the development of MSA.
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The role of the adaptive immune response in MSA is explored in the current study by
demonstrating elevated numbers of CD8α positive lymphocytes in the pontocerebellar tracts of
MSA pons tissue. CD8α is a glycoprotein that is primarily a marker of cytotoxic T lymphocytes
(Andersen et al., 2006; Terry et al., 1990). However, CD8α can also found to a much lesser
extent on natural killer (NK) cells, which do not express T cell receptor (TCR) (Terry et al.,
1990). Like the TCR, CD8 binds to a major histocompatibility complex (MHC) molecule,
specifically class I MHC protein. The CD8 glycoprotein forms either a homodimer consisting of
two alpha chains, or more commonly a heterodimer consisting of an alpha and beta chain (Terry
et al., 1990).
Therefore, as previously stated, the first objective of this study is to determine if CD68
and CD33 have an increased presence in the pontocerebellar tracts of MSA pons, and to
determine if more CD8α positive lymphocytes are observed in these tracts. The increased
presence of these immune proteins indicates innate and adaptive immune responses in a region of
the pons previously shown to contain α-Syn immunoreactivity (Langerveld et al., 2007).
Methods and Materials
Tissue Collection and Patient Demographics
Human pons tissue from MSA and control patients was obtained from the New York
Brain Bank (NYBB) at Columbia University, where the tissue was fixed in formalin and
paraffin-embedded. A microtome was used to cut 10 µm thick sections. A definite diagnosis of
MSA was verified at NYBB by performing a pathological analysis on postmortem tissue
(Langerveld et al., 2007). No known neuropathology was detected in control patients. Table 1
shows the profiles of MSA and control patients that were used for this study to analyze the
presence of CD68, CD33, and CD8α in the pons.
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NYBB ID

Age

Gender

Diagnosis

Stain

T638

78

Male

Control

CD68, CD33, CD8α

T4233

74

Male

Control

CD68, CD33, CD8α

T343

59

Male

Control

CD68, CD33, CD8α

T220

57

Female

Control

CD68, CD33, CD8α

T4259

49

Male

Control

CD68, CD33, CD8α

T3569

N/A

N/A

MSA

CD68, CD33

T29

68

Male

MSA

CD68, CD33, CD8α

T80

77

Female

MSA

CD68, CD33

T71

68

Female

MSA

CD68, CD33

T330

73

Female

MSA

CD68, CD33

T68

65

Female

MSA

CD8α

T183

69

Male

MSA

CD8α

T338

67

Female

MSA

CD8α

T3873

61

Male

MSA

CD8α

Table 1. Patient Age and Diagnosis from the New York Brain Bank at Columbia University. Patient diagnosis is
described as MSA (Multiple System Atrophy) or Control (having no known neuropathology). Pons tissue from each
patient was stained for CD68 and CD33 and/or CD8α as indicated above.

Immunohistochemistry of CD68 and CD33
To perform immunohistochemistry methods for CD68 and CD33, pons brain sections
prepared by the NYBB. One slide was prepared per patient. Sections were deparaffinized in five
xylene washes for 5 minutes each. The sections were then rehydrated using a series of ethanol
washes that decreased in concentration from 100%, to 95%, to 70%. Sections were then washed
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in phosphate buffered saline (PBS) for five minutes to remove any remaining ethanol. Heatmediated antigen retrieval was performed by steaming the sections in sodium citrate buffer (pH
6) for thirty minutes. The tissue was cooled for at least twenty minutes before two PBS washes
for five minutes each. A blocking solution was prepared containing 2% BSA and 0.3M glycine
in PBS (glycine binds and removes aldehydes that remain after fixation to help prevent
autofluorescence) with 0.1% Tween-20 (PBST). To block non-specific staining, the sections
were incubated in the blocking solution for two hours at room temperature. The primary
antibody, mouse anti-human CD33 monoclonal antibody (Abcam), was diluted to 1:100 in
blocker. The sections were then incubated in primary antibody overnight at 4°C. A negative
control was prepared using an MSA pons section, for which processing excluding incubation
with primary antibody. The sections were then washed in three PBST washes for five minutes
each. The secondary antibody to detect CD33, Alexa Fluor 488 conjugated goat anti-mouse
antibody (Abcam), was diluted 1:250 in blocker. Sections were incubated in the secondary
antibody for one hour at room temperature. Incubation in secondary antibody was followed by
two 5-minute PBST washes then two 5-minute PBS washes. Sections were then incubated again
in blocking solution for two hours at room temperature. The primary antibody, rabbit anti-CD68
polyclonal antibody against a synthetic peptide corresponding to the C terminus of human CD68
(Abcam), was diluted to 1:100 in blocker. The sections were incubated in primary antibody
overnight at 4°C. A negative control was processed using an MSA pons section (the same
negative control slide used for CD33) which excluded incubation with primary antibody. The
secondary antibody to detect CD68, Alexa Fluor 594 conjugated goat anti-rabbit antibody
(Abcam), was diluted to 1:250 in blocker. Following incubation in secondary antibody, slides
were washed using three 5-minute PBST washes. The sections were dehydrated and cleared
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using increasing dilutions of 70%, 95%, and 100% ethanol, followed by two 2-minute xylene
washes. The slides were coverslipped using Permount mounting medium.
Immunohistochemistry of CD8α
For immunohistochemistry methods of CD8α, sections were deparaffinized and
rehydrated before performing heat-mediated antigen retrieval as described above. One slide was
prepared per patient. The tissue was allowed to cool for 20 minutes and then washed in PBS for
five minutes. Tissue was then washed in 3% hydrogen peroxide for five minutes followed by two
5-minute PBS washes. A blocking solution was then prepared using 3% normal horse serum and
0.4% Triton X-100 in PBS. To block non-specific staining, the sections were incubated in the
blocking solution for two hours at room temperature. The primary antibody, CD8α mouse antihuman CD8α monoclonal antibody (Santa Cruz), was diluted 1:100 in blocker. The sections
were incubated in primary antibody overnight at 4°C. A negative control was prepared using an
MSA pons section, for which preparation excluded incubation with primary antibody. The
sections were washed three times in tris-buffered saline with 0.1% Tween-20 (TBST) for five
minutes each before incubation in secondary antibody, ImmPRESS-AP horse anti-mouse (Vector
Laboratories), for thirty minutes. Incubation in secondary antibody was followed by three 5minute TBST washes. Alkaline Phosphatase (AP) substrate was prepared using Red Alkaline
Phosphatase (Red AP) Substrate Kit (Vector Laboratories). Levamisole Solution (Vector
Laboratories) was added to the alkaline phosphatase substrate solution to block endogenous
alkaline phosphatase. The sections were then submerged in AP substrate until color had
developed (5-15 minutes). The sections were washed in ultrapure water, then tris-buffered saline
(TBS), for five minutes each to remove any excess AP substrate. Sections were washed,
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dehydrated, and cleared as described above. The slides were then coverslipped using
VectaMount permanent mounting medium.
Image Analysis of CD68 and CD33
MSA and control pons sections stained for CD68 and CD33 were visualized and
photographed using a Nikon Confocal Microscope C2/C2si. Images (635 x 635 µm) were
acquired from five MSA patients and five control patients. A total of 15 images were captured
from the pontocerebellar tracts of each patient. For analysis, the tracts were divided into either
dorsal pontocerebellar (DPC) tracts, mid pontocerebellar (MPC) tracts or ventral pontocerebellar
(VPC) tracts according to location. The DPC tracts were identified as the transverse fiber tracts
located immediately ventral to the medial lemiscus (Vanderah and Gould, 2015). The MPC tracts
were recognized as the transverse fiber tracts located in the central portion of the tissue sections
running between the corticopontine fiber tracts (Vanderah and Gould, 2015). The VPC tracts
were identified as the transverse fiber tracts running between and ventral to the corticospinal and
corticobulbar fiber tracts (Vanderah and Gould, 2015). For each of the three regions, five
random, non-overlapping images were captured using a 20X objective. Images were taken by
moving from one side of the tissue to the other, beginning with the dorsal tracts and moving
toward the ventral tracts. The staining patterns were quantitatively analyzed using NIS elements
and Fiji software (nih.gov). NIS elements software was used to separate each merged image into
two separate images; one displaying only Alexa Fluor 594 (red) and the other displaying only
Alexa Fluor 488 (green). Images were calibrated to 0.62 μm/pixel. For each image, the
pontocerebellar tracts were isolated by carefully selecting the tract area and clearing adjacent
tracts and identified blood vessels from the image; the area of the selected tracts was then
measured. ROI manager was utilized to ensure the same area was selected for red and green
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channels of the same image. The immunostained area was selected in each picture by using the
Max Entropy algorithm under the color threshold tool; this ensured no bias when selecting the
stained area. For each image, the immunostained area was measured and normalized to the area
of the pontocerebellar fiber tracts. For CD68 and CD33 images shown (Figure 1), brightness and
contrast were slightly adjusted using Adobe Photoshop and Excel to aid in visualization.
Image Analysis of CD8α
MSA and control pons sections stained for CD8α were visualized and photographed
using a Spot Cooled Color Digital Camera system (Diagnostic Instruments, Inc, Sterling Heights,
MI) attached to a Nikon Eclipse E600 Microscope. Images (685 x 538 µm) were acquired from
five MSA patients and five control patients. A total of 15 images were collected from the
pontocerebellar tracts of each patient. For analysis, the tracts were deemed either dorsal
pontocerebellar (DPC) tracts, mid pontocerebellar (MPC) tracts or ventral pontocerebellar (VPC)
tracts according to location. For each of the tract regions, five random, non-overlapping images
were captured using a 20X objective. Images were taken by moving from one side of the tissue
to the other, beginning with the dorsal tracts and moving toward the ventral tracts. The staining
patterns were quantitatively analyzed using Fiji software (nih.gov). Images were calibrated to
1.92 pixels/µm. The images were quantitatively analyzed using the cell counting tool. Tissue and
perivascular immunoreactive cells within the pontocerebellar tracts were included in the count;
cells in the adjacent tracts were omitted. The pontocerebellar tracts in each image were carefully
selected and the area was measured. The cell count was normalized to the area of pontocerebellar
tracts in each image.
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Statistical Tests
Statistical tests were run using SPSS software. A Three-factor mixed ANOVA (one
between- and two within-subjects factors) was used to show differences in CD68 and CD33
immunoreactivity between MSA and control patients, if differences occurred between the DPC,
MPC, and VPC fiber tracts, and to detect any differences between CD68 and CD33 stains within
both MSA and control tissues. Similarly, a three-factor mixed ANOVA (one between- and two
within-subjects factors) was used to detect differences in CD8α immunoreactivity between MSA
and controls, and to show any differences in CD8α immunoreactivity between the DPC, MPC,
and VPC tracts within MSA and control tissues. A p-value of p≤ 0.05 was considered
statistically significant.
Results
Increased Presence of CD68 and CD33 in the Pontocerebellar Tracts in MSA Pons
IHC was performed on sections of pons tissue to test the hypothesis that there is an
increased presence of CD68 and CD33 in the pontocerebellar tracts of MSA patients when
compared to non-MSA controls. Images from immunostained tissue (Figure 1) show the
distribution of cells expressing CD68 and CD33 in the pontocerebellar fiber tracts of an MSA
and control patient. Figure 2 shows MSA stained tissue with a negative control (primary
antibody omitted). A mixed three-factor ANOVA (one between- and two within-subjects factors)
showed that CD68 and CD33 protein expression is significantly higher in MSA pontocerebellar
tracts when compared to controls (p = 0.014) (Figure 3). Comparison of the DPC, MPC, and
VPC tracts showed no significant difference in CD68 and CD33 expression between these three
regions within both MSA and controls (p = 0.821). Although CD68 and CD33 are both
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expressed in macrophage and microglia (Spöttl et al., 2001), the immunoreactivity of CD68 was
significantly higher than CD33 (p = 0.012).

Figure 1. Immunohistochemistry of CD68 and CD33 in the Pontocerebellar Tracts. Images showing immunostaining
of CD68 and CD33 on transverse sections from the pons of an (A) MSA patient and (B) control patient taken using
20X objective lens (scale bar = 100 µm). (1a-1c, 2a-2c) Images showing immunostaining of CD68 and CD33 were
taken using 60X water emersion objective (scale bar = 50µm). (1a, 2a) Double labeling of CD33 and CD68. (1b, 2b)
CD33 labeled with Alexa Fluor 488 (1c, 2c) CD68 labeled with Alexa Fluor 594.
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A

B

Figure 2. Immunohistochemistry of CD68 and CD33 in the Pontocerebellar Tracts with Negative Control. (A)
Staining of CD68 and CD33 on sections from the pons of MSA patient T-3569 and (B) negative control (no primary
antibody). Images were taken using 20X objective (scale bar = 100 µm).

CD68

CD33

1.8

*

Percent Area Stained

1.6

1.4
1.2

1
0.8
0.6
0.4
0.2
0

Dorsal

Mid

Ventral

Dorsal

MSA

Mid

Ventral

Control

Figure 3. Average Percent Area of CD68 and CD33 Immunostaining in the Pontocerebellar Tracts of MSA and
Control Patients. Data are represented as the mean ± standard error of the mean (SEM). A three-factor mixed
ANOVA revealed CD33 and CD68 staining is significantly higher in MSA pontocerebellar tracts when compared to
controls (p ≤ 0.05, n = 5). Comparison of the dorsal, mid, and ventral pontocerebellar tracts showed no significant
difference in CD33 and CD68 staining between these regions within both MSA and controls (p ≥ 0.05).
*Significantly (p ≤ 0.05) different from control
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Elevated Numbers of CD8 Positive Lymphocytes in the Pontocerebellar Tracts in MSA Pons
IHC was completed on sections of pons tissue to test the hypothesis that the
pontocerebellar tracts of MSA pons show an increased number of CD8+ lymphocytes when
compared to non-MSA controls. Images from immunostained pons tissues (Figure 4) show the
distribution of cells expressing CD8α in the pontocerebellar tracts of an MSA and control
patient. Figure 5 shows MSA stained tissue and negative control (primary antibody omitted). A
three-factor mixed ANOVA (one between- and two within-subjects factors) showed increased
immunoreactivity of CD8α in MSA pontocerebellar fiber tracts when compared to controls (p =
0.008) (Figure 6). Comparison of the DPC, MPC, and VPC tracts showed no significant
difference in CD8α expression between these three regions within both MSA and controls (p =
0.546).
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Figure 4. Immunohistochemistry of CD8α in the Pontocerebellar Tracts. Images showing immunostaining of CD8α
on sections from the pons of (A) MSA and (B) control patients were taken using 20X objective lens (scale bar = 100
µm). CD8α positive lymphocytes in MSA (1,2) and control (3,4) in the pontocerebellar tracts (arrows) were taken
using 100X objective lens (scale bar = 25 µm).

A

B

Figure 5. Immunohistochemistry of CD8α in the Pontocerebellar Tracts with Negative Control. Staining of CD8α
on sections from the pons of MSA patient T-183 and (B) negative control were taken using 20X objective lens (scale
bar = 100 µm).
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Figure 6. Average Number of CD8α Positive Cells Normalized to the Area of the Pontocerebellar Tracts. Data are
represented as the mean ± SEM. A three-factor mixed ANOVA revealed the number of CD8α immunoreactive cells
is significantly higher in MSA pontocerebellar tracts when compared to controls (p ≤ 0.05, n = 5). Comparison of
the dorsal, mid, and ventral pontocerebellar tracts showed no significant difference in CD8α staining between these
regions within both MSA and controls (p ≥ 0.05). *Significantly (p ≤ 0.05) different from control.

Discussion
This study demonstrates an elevated innate and adaptive immune response associated
with neuroinflammation in the pontocerebellar tracts of MSA pons tissue. The results of these
data parallel the cerebellar symptoms in MSA, since the pontocerebellar tracts connect the
cerebellum and pons, and are involved in relaying information regarding movement (Gartner and
Patestas, 2009; Haines, 2012). Increased staining of microglia and macrophage markers, CD68
and CD33, was observed in the pontocerebellar tracts of MSA pons when compared to control
tissue. The number of CD8α immunoreactive cells was also higher in the pontocerebellar tracts
of MSA pons compared to control tissue. There was no significant difference in CD68 and
CD33, or CD8α staining between DPC, MPC, and VPC tracts.
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The increase of microglia/macrophage associated proteins and CD8α positive
lymphocytes are indicative of neuroinflammation. Previous Affymetrix DNA microarray
analysis in our lab demonstrated the upregulation of multiple inflammatory and stress response
genes in MSA pons (Langerveld et al., 2007), which supports the results of the current study.
This inflammatory response may be the result of α-Syn aggregates, which induce the release of
pro-inflammatory cytokines from microglia and astrocytes (Fellner et al., 2013; Lee et al., 2010a;
Zhang et al., 2005).
Multiple studies have shown the involvement of microglia in the progression of αsynucleinopathies, and their activation via direct contact with α-Syn (Fellner et al., 2013; Su et
al., 2008; Zhang et al., 2005). The increased presence of CD68 and CD33 in the pontocerebellar
tracts of MSA pons suggest the involvement of microglia-like cells. Since the purpose of this
study was to determine if increased presence of innate immune cells occurred in MSA brain
tissue, CD68 and CD33 were ideal markers, since these proteins are expressed in microglia,
macrophages, and potentially other cells of the innate immune system. Microglia are the primary
innate immune cell of the brain; however, it is possible that macrophages and or other CD68 and
CD33 positive cells are present. Since, we did not use a marker that was specific to either
microglia or macrophages, we refer to the CD68 and CD33 immunoreactive cells we observed as
microglial-like. Future studies may help determine the specific population of immune cells
involved in the progression of MSA. While these data suggest a greater presence of reactive
microglia-like cells, additional analysis is necessary to determine if the increased stained area of
CD68 and CD33 indicates increased infiltration of microglia-like cells and/or if protein
expression is elevated in individual cells. Furthermore, the immunoreactivity of CD68 was
significantly higher than CD33, which may indicate a greater protein expression of CD68
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compared to CD33 within the observed microglia-like cells. Future studies are needed to further
define CD68 and CD33 protein expression and to determine if mRNA levels are dysregulated in
MSA.
Elevated numbers of CD68 immunoreactive microglia have been identified in multiple
neurodegenerative disorders, including PD, AD, MS, and MSA (Fiala et al., 2002; Ishizawa et
al., 2004; Hirsch and Hunot, 2009; Stadelmann et al., 2002; Theodore et al., 2008). CD68 is
associated with inflammation and phagocytosis, and while expressed on both resting and
activated microglia, increased expression is observed in activated cells (Chistiakov et al., 2017;
Papageorgiou et al., 2016; Song et al., 2011). Increased presence of CD68 in MSA
pontocerebellar tracts suggests inflammation involving reactive microglial-like cells.
Recent studies suggest that CD33 is more than just a microglia marker; it also implicated
in the pathology of AD (Bradshaw et al., 2013; Griciuc et al., 2013). In fact, overexpression of
CD33 correlates with impaired clearance of amyloid beta (Aβ) (Bradshaw et al., 2013; Jiang et
al., 2014; Griciuc et al., 2013). In addition to the inhibition of protein clearance, CD33 is also
involved in modulation of cytokine secretion, and inhibition of immune cell functions (Crocker
et al., 2007; Jandus et al., 2011; Jiang et al., 2014; Lajaunias et al., 2005). Elevated levels of
CD33 protein have been found in patients with AD (Bradshaw et al., 2013; Griciuc et al., 2013),
where it is associated with increased numbers of microglia (Griciuc et al., 2013). Just as
microglia play a role in the clearance of Aβ, microglia are important for the clearance of
misfolded α-syn in MSA (Lee et al., 2008). It has been shown that degradation of α-Syn
aggregates is slowed in activated microglia (Lee et al., 2008). Increased presence of CD33 in
MSA pontocerebellar tracts may indicate that it has a similar role in MSA, contributing to
reduced clearance of α-Syn aggregates by microglia. While CD33 has a detrimental role in
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impairing microglia mediated Aβ clearance, CD33 has also been shown to inhibit monocyte
production of pro-inflammatory cytokines (Lajaunias et al., 2005). While the function of CD33
in MSA is unknown, it is possible that CD33 may also play a neuroprotective role by decreasing
the production of inflammatory cytokines.
While previous studies have looked at defining the role of microglia in
neuroinflammation and the progression of MSA (Ishizawa et al., 2004; Stefanova et al., 2007),
few studies have looked at the adaptive immune system in MSA pathology. Results of this study
showed a significant increase in the number of cells stained for CD8α, a cytotoxic lymphocyte
marker, in the pontocerebellar tracts of MSA patients when compared to controls. There was no
significant difference in the number of CD8α immunoreactive cells between the DPC, MPC, and
VPC tracts in either MSA or control pons. CD8α is primarily expressed on mature cytotoxic T
cells, but it can be found to a lesser extent in natural killer (NK) cells (Andersen et al., 2006;
Terry et al., 1990). The increased number of CD8 positive cells suggests an increased
infiltration of cytotoxic T lymphocytes throughout all regions of the pontocerebellar tracts in
MSA pons tissue.
As previously described, the increase of microglia and macrophage associated proteins in
MSA pontocerebellar tracts indicates a neuroinflammatory response. The release of
inflammatory cytokines, such as IL-12, are shown to provide one of the signals involved in the
differentiation of naive T cells into cytotoxic T cells (Curtsinger et al., 1999). In addition to
promoting T cell maturation, the release of inflammatory cytokines promotes the proliferation of
differentiated T cells (Curtsinger et al., 1999). Although the involvement of cytotoxic T cells is
not well characterized in MSA, the infiltration of CD8+ T cells and have been observed in both
PD (Brochard et al., 2009) and MS (Tzartos et al., 2008). Interestingly, in contrast to PD and
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MS, slight decreases in the number of CD8+ T cells have been observed in AD (RichartzSalzburger et al., 2007).
The increased number of CD8 positive cells in the MSA pons is an interesting
phenomenon, as cytotoxic T cells are crucial in defending the body from intracellular pathogens
including viruses and bacteria (Anderson et al., 2006). The T cell antigen receptor (TCR) on
CD8 T cells, recognizes antigens as peptides bound to major histocompatibility complex (MHC)
Class I molecules, which are expressed by most nucleated cells (Andersen et al., 2006).
Additional signaling is then required to activate cytotoxic T cells, including interactions between
B7 proteins expressed by the antigen-presenting cell (APC) and CD28 on the T cell (Andersen et
al., 2006). The primary APCs in the brain are microglia, and as previously stated, these cells are
thought to be important for the internalization and clearance of alpha-synuclein (Lee et al.,
2008). It is possible that in MSA, cytotoxic T cells are activated in part via recognition of α-Syn
peptides presented by microglia and or other cells in the CNS. Upon activation, cytotoxic T cells
use cell to cell contact and or cytokines to induce cell death of target cells via apoptosis
(Andersen et al., 2006). Therefore, the expansion of cytotoxic T cells in the MSA brain may
contribute to the loss of glial cells.
While the increased number of cytotoxic lymphocytes in MSA pontocerebellar tracts are
presumed to be cytotoxic T cells, additional analysis is required to confirm whether these
lymphocytes are indeed CD8+ T cells or a combination of CD8+ T cells and NK cells. Future
studies should include additional T cell markers. One such marker is CD3, which is specific T
cell receptor protein expressed in both CD4+ and CD8+ T cell subtypes (Kelly et al., 1988; Male
et al., 2012). If these cells are confirmed to be cytotoxic T cells, further investigation should be
conducted to determine whether or not these cells are targeting a specific epitope(s). Since both
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CD8+ and CD4+ T cells are implicated in other neurodegenerative disease, future studies should
also include staining for CD4+ cells. It would be interesting to identify if one T cell subtype
predominates over the other, to better characterize the cytotoxic and/or potential neuroprotective
role of T cells in MSA. Additional studies should also involve double labeling of α-Syn and the
three immune markers presented in this study, to determine if colocalization occurs between
these immune proteins and α-Syn.
Conclusion
In conclusion, this work demonstrated increased immunostaining of CD68, CD33, and
CD8α, in the pontocerebellar tracts of postmortem MSA pons tissue, a region that was
previously shown to contain a high density of α-Syn aggregates. These data suggest an innate
and adaptive immune response mediated by microglia and cytotoxic T lymphocytes,
respectively, in the pontocerebellar tracts of MSA pons tissue. While the stained area of CD68
and CD33, and the number of CD8α positive cells was significantly higher in MSA
pontocerebellar tracts, there was no significant difference in staining between the three regions of
the tracts (DPC, MPC, and VPC). It is therefore likely that all areas of the tracts are similarly
affected. This research makes a valuable contribution to MSA research in that it better defines
the involvement of immune proteins in affected brain areas, as well as how the immune response
in MSA compares to other neurodegenerative diseases.
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CHAPTER III

EFFECTS OF ALPHA-SYNUCLEIN ON CELL VIABILITY, MITOCHONDRIAL
FUNCTION, AND NUCLEAR MORPHOLOGY IN A CELL CULTURE MODEL OF MSA

The Function of Alpha-Synuclein
Alpha-synuclein is a 140 amino-acid cytoplasmic protein, primarily found in the
presynaptic terminals of neurons in the CNS, and is involved in the pathogenesis of PD,
Dementia with Lewy Bodies, and MSA (Marques and Outeiro, 2012; Norris et al., 2004). While
there is limited information regarding the function of α-Syn, it is thought to play a role in the
synaptic vesicle cycle, neurotransmitter release, and neuronal differentiation (Bendor et al.,
2013; Emamzadeh, 2016; Marques and Outeiro, 2012). Mutations and expression changes in αSyn are associated with disease, and include changes in mitochondrial function, cell morphology,
and cell death. In this study, the effect of α-Syn on cell metabolism, cell viability, mitochondrial
function, and cell morphology was investigated using C6 glioma cells treated with exogenous αSyn as a cell culture model of MSA.
Alpha-synuclein is expressed in other tissue types including red blood cells (Barbour et
al., 2008), but it is abundant in neuronal tissue. Although α-Syn is localized to the synapse in
neurons, it is thought that its function might differ from other presynaptic proteins (Murphy et
al., 2000; Norris et al., 2004; Withers et al., 1997). Two studies in hippocampal neurons have
demonstrated that α-Syn is expressed later than other presynaptic proteins, such as synaptophysin
and synapsin I (Murphy et al., 2000; Withers et al., 1997). The delayed localization of α-Syn
tosynapses (after synaptic development) indicates that it may be more involved in the
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maintenance of synapses rather than formation (Murphy et al., 2000; Norris et al., 2004; Withers
et al., 1997).
Alpha-synuclein is thought to interact with multiple proteins at presynaptic terminals
(Burré 2015). One of these protein interactions involves the SNARE protein synaptobrevin-2
(Burré et al., 2010; Burré 2015). Alpha-synuclein may directly promote the assembly of the
SNARE complex by binding to synaptobrevin-2 (Burré et al., 2010). The SNARE complex is
important for mediating the fusion of synaptic vesicles, thus influencing neurotransmitter release
(Palfreyman and Jorgensen, 2008). A study by Burré et al., demonstrated the role of α-Syn in
aging animals via αβγ-synuclein triple knockout mice, which showed decreased SNAREcomplex assembly with age (Burré et al., 2010). The introduction of wild-type (WT) α-Syn into
cultured neurons from these transgenic mice increased SNARE-complex assembly (Burré et al.,
2010).
Consistent with the study by Burré et al, other studies have shown involvement of α-Syn
in the synaptic vesicle cycle (Nemani et al., 2010). In neuronal cell cultures, the overexpression
of α-Syn effects synaptic vesicle cycle by inhibition of exocytosis (Nemani et al., 2010).
Overexpression of α-Syn decreases the size of the readily releasable synaptic vesicle pool and
the vesicle recycling pool (Nemani et al., 2010). The readily releasable synaptic vesicle pool are
vesicles docked and ready for exocytosis, while the recycling pool continues release after readily
releasable pool is exhausted (Alabi and Tsien, 2012).
As a neuronal protein, it is thought that α-Syn may also influence neuronal differentiation
(Oliveira et al., 2015; Winner et al., 2012). One study found an increase in neuronal
differentiation and neurogenesis in the dentate gyrus in α/β-synuclein knockout transgenic mice
(Winner et al., 2012). In addition, the overexpression of α-Syn in mice via injection of a WT
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synuclein-GFP retrovirus negatively affected neurite outgrowth in new neurons within the
dentate gyrus (Winner et al., 2012). Similarly, another study found that cultured neuronal
progenitor cells overexpressing α-Syn due to SNCA gene triplication experienced problems with
differentiation, demonstrating a less developed network when compared to controls (Oliveira et
al., 2015). These studies indicate that α-Syn may have a negative effect on the differentiation of
neuronal cells.
Role of Alpha-Synuclein in Neurodegeneration
Alpha-synuclein appears to play a role in normal operation of the synaptic vesicle cycle.
However, the full range of its functions are still undefined. Despite its normal function remaining
a mystery to some degree, it is evident that mutations and expression changes of α-Syn
contribute to disease, including MSA.
Mutations in SNCA Gene are Associated with Neurodegeneration
MSA is a sporadic disease, and while various environmental hazards been identified in
MSA (Nee et al., 1991), genetic mutations may also be a risk in disease onset. Point mutations
and single-nucleotide polymorphisms in the SNCA gene have been identified in PD, and
polymorphisms in the SNCA gene are also associated with MSA (Marques and Outeiro, 2012).
Several studies found missense mutations including A53T, A30P, and E46K of the SNCA gene in
PD patients (Krüger et al., 1998; Polymeropoulos et al., 1997; Zarranz et al., 2004). In several
mammalian cell lines, A53T and E46K mutations are associated with increased phosphorylation
of α-Syn when compared to WT (Mbefo et al., 2015). This is noteworthy, because increased
phosphorylation of α-Syn may be associated with inclusion formation (Smith et al., 2005).
Oxidative stress increases phosphorylation at the Ser-129 residue in neuronal cells in association
with a greater density of inclusions (Smith et al., 2005). As mentioned previously, triplication of
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the SNCA gene increases α-Syn expression and negatively impacts neuronal differentiation and
maturation (Oliveira et al., 2015).
Effect of α-Syn on Cell Viability
Many studies investigating the influence of α-Syn on cell viability have focused on
neuronal survivability. Alpha-synuclein is normally produced by neurons, and in vitro
experiments have shown that it can be taken up from the extracellular environment via
endocytosis (Desplats et al., 2009). The uptake of exogenous α-Syn by neurons is associated with
nuclear fragmentation and caspase-3 activation, indicating apoptotic changes (Desplats et al.,
2009). The overexpression of mutant α-Syn in vivo is also associated with cell death (Martin et
al., 2006). It is thought that the aggregation of α-Syn in the form of oligomers is cytotoxic
(Waxman and Giasson et al., 2009), just as amyloid beta (Aβ) intermediates may be pathogenic
in Alzheimer's disease (Verma et al., 2015; Waxman and Giasson et al., 2009). Specific types of
exogenous α-Syn oligomers lead to an increase of intracellular calcium by increasing membrane
permeability via the formation of pores (Danzer et al., 2007). Interestingly, elevated intracellular
calcium levels have been implicated in the pathogenesis of Alzheimer’s disease (Mattson and
Chan, 2001). These specific spherical oligomers are also associated with a decrease in cell
number (Danzer et al., 2007).
While the effect of α-Syn on neuronal cells is becoming well established, its impact on
glial cells should also be examined. Contrary to other α-synucleinopathies, the primary
characteristic of MSA is the accumulation of α-Syn inclusions in oligodendrocytes (Burn and
Jaros, 2001; Spillantini and Goedert, 2000; Trojanowski and Revesz, 2007). This is an intriguing
pathological trademark, since α-Syn mRNA is typically not found in human oligodendrocytes
(Reyes et al., 2014). It is interesting to note that in MSA, cell death via apoptosis is more
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prevalent in oligodendrocytes than it is in neurons (Probst-Cousin et al., 1998). The
overexpression of WT α-Syn in glial cells results in increased apoptosis and susceptibility to
oxidative stress (Stefanova et al., 2001).
Alpha-Synuclein in Mitochondrial Activity and Interactions
One of the mysteries in understanding the function of α-Syn lies in its interactions with
mitochondria. Therefore, this study looks at identifying the relationship between α-Syn and
mitochondrial dysfunction. It has been proposed that the N-terminus of α-Syn contains a
mitochondrial targeting sequence (Devi et al., 2008). The translocase of the outer membrane
(TOM) complex of mitochondria appears to be important for the import of α-Syn into the
mitochondria where it is found predominantly near the mitochondrial inner membrane (Devi et
al., 2008). Multiple studies have investigated the contribution of α-Syn to mitochondrial
dysfunction. It has been demonstrated that overexpression of mutant and WT α-Syn in vitro
results in the release of apoptotic protein, cytochrome c, from mitochondria, as well as greater
colocalization between α-Syn and mitochondria (Parihar et al., 2008). Rotenone, an inhibitor of
mitochondrial complex I (Li et al., 2003), was found to be more effective in decreasing ATP
levels in cells overexpressing α-Syn (Shavali et al., 2008). This suggest that increased expression
of α-Syn causes mitochondria to be more susceptible to mitochondrial toxins (Shavali et al.,
2008). Additionally, overexpression of α-Syn in a murine hippocampal cell line showed
morphological changes in mitochondria in conjunction with reduced mitochondrial activity (Hsu
et al. 2000). Mitochondrial activity can potentially be rescued using anti-oxidant treatment (Hsu
et al. 2000). Consistent with morphological changes found by Hsu et al., transgenic mice with
the A53T SNCA mutation experience mitochondrial morphological changes and mitochondrial
DNA damage (Martin et al., 2006).
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Alpha-Synuclein in Cell Morphology Changes
Certain cellular morphological changes are associated with the accumulation of α-Syn in
oligodendroglia (Lindersson et al., 2005; Song et al., 2007). Increases in oligodendrocyte size as
well as α-Syn positive oligodendroglia have been observed in MSA (Lindersson et al., 2005;
Song et al., 2007). Additionally, p25α, a component of myelin, relocalizes from myelin to the
cell body of oligodendrocytes (Lindersson et al., 2005; Song et al., 2007). In MSA, GCIs
containing α-Syn are localized near to the nucleus in oligodendrocytes; the presence of GCIs is
accompanied by enlarged nuclei compared to cells without GCIs (Ahmed et al., 2012).
While this study has shown the contribution of the immune system in a brain region
affected by α-Syn, it is important to determine how α-Syn directly affects glial cells, the primary
cells affected in MSA. It is likely that a combination of increased immune activity and impaired
glial cell function followed by cell death leads to the pathology associated with MSA. As
previous literature suggests, α-Syn is involved with neurodegeneration via mitochondrial
interactions and changes in cell viability. There are also associated changes in cell morphology.
Based on these observations, the second objective of this study is to investigate glial cell
pathology, including cell metabolism and viability, mitochondrial function, and cell morphology,
with a cell culture model of MSA comprised of C6 glioma cells treated with exogenous α-Syn.
Methods and Materials
CCK-8 Assay to Measure Dehydrogenase Activity
C6 rat glioma cells were obtained from ATCC (ATCC® CCL-107™). C6 cells were
cultured in F-12K medium containing 15% horse serum and 2.5% fetal bovine serum. Cell
Counting Kit-8 (CCK-8) (Dojindo) was used to measure the amount of dehydrogenase activity in
C6 cells incubated with α-Syn for either two or four days, in order to determine metabolic
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activity. C6 cells were grown in T25 flasks to 100% confluency (3 days). Cells were then
incubated in a 1X Trypsin-EDTA solution (ATCC) at 37⁰C until completely detached. Cells
were resuspended in culture medium to a density of 160,000 cells/ml for the 2-day incubation or
40,000 cells/ml for the 4-day incubation. Cells were plated into 96-well plates by adding 100 µl
of cell suspension into each well (16,000 cells/well or 4,000 cells/well). Cells were incubated
overnight before replacing the medium in wells with medium containing various concentrations
of α-Syn. No cells were plated along the edge wells; instead these wells were filled with
approximately 150 µl of sterile deionized water. Cells were plated in this manner to prevent
evaporation of medium during incubation. WT α-Syn (rPeptide) was reconstituted to a
concentration of 1mg/ml. Cells were treated in duplicate at the following concentrations of αSyn: 0 µg/ml (control), 2 µg/ml, 4 µg/ml, 8 µg/ml, 16 µg/ml, 32 µg/ml, and 64 µg/ml. Following
either two days or four days of incubation, Cell Counting Kit-8 (CCK-8) (Dojindo) was used to
determine the amount of dehydrogenase activity. 10 µl of the CCK-8 solution (containing a
water-soluble tetrazolium salt (WST-8)) was added into each of the treated or untreated wells,
and incubated at 37⁰C for two hours. Following incubation, the optical density (OD) of each well
was measured spectrophotometrically at 450 nm using Gen5 software on an Epoch microplate
spectrometer (Bio-Tek). Final OD values were obtained by subtracting the optical density value
of blank wells, which consisted of culture medium plus 10ul of CCK-8 solution. To ensure αSyn did not impact WST-8 development, tests were performed by replacing with medium
containing 16 µg/ml of α-Syn into additional control wells at the same time as the CCK-8
solution. After the 2-hour incubation, OD readings of the short term treated wells were
comparable to untreated cells (data not shown). Following spectrophotometrical analysis, cell
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counts were determined for each dose, as described below using trypan blue. The OD readings
were then normalized to the number of cells per treatment group.
Trypan Blue Cell Viability Assay
C6 Cells Incubated for Two Days with α-Syn
As described previously, C6 cells were incubated in 96 well plates for two days with
various concentrations of α-Syn. Following OD measurements of CCK-8 solution, medium was
removed from the wells, and cells were washed with 100 µl of 1X Hank’s balanced salt solution
(HBSS). The removed medium was placed into appropriately labeled Eppendorf tubes (one tube
per treated or untreated group). Before discarding the HBSS wash, it was examined to ensure no
cells were lost during the wash step. Cells were then trypsinized by adding 100 µl of 1X TrypsinEDTA solution and incubating the plate at 37⁰C until cells completely detached. The trypsinized
cell suspension from each treated or untreated group was removed and placed into an
appropriately labeled Eppendorf tube (one tube per treated or untreated group). Each well was
then washed with 100 µl of medium to ensure all cells were removed; the medium was removed
from the wells and placed in the appropriately labeled tubes. Next, 100 µl of the cell suspension
was mixed with 100 µl of 0.4% trypan blue in PBS (1:2 dilution). The number of live and/or
dead cells was determined by adding 10μl to a hemocytometer and performing cell counts at 10x
objective using a Nikon Eclipse E600 Microscope. The number of live cells per well was
determined using the equation: average number of live cells per corner square x 104 x 0.6 (total
volume (ml) of cell suspension from both wells) = number of cells per 100 µl of suspension. The
same equation was used to calculate the number of dead cells; percentage of live versus dead
cells was then determined.
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C6 Cells Incubated for Four Days with α-Syn
As described previously, C6 cells were incubated in 96 well plates for four days with
various concentrations of α-Syn. Following OD measurements of CCK-8 solution, medium was
removed from the wells, and cells were washed with 100 µl of 1X HBSS. Before discarding, the
removed medium and HBSS wash were examined to ensure no cells were lost during the wash
step. Cells were trypsinized by adding 100 µl of 1X Trypsin-EDTA solution and incubating the
plate at 37⁰C until cells completely detached. The trypsinized cell suspension from each treated
or untreated group was removed and placed into an appropriately labeled Eppendorf tube (one
tube per treated or untreated group). Each well was then washed with 100 µl of medium to
ensure all cells were removed; the medium was removed from the wells and placed in the
appropriately labeled tubes. Next, 100 µl of the cell suspension was mixed with 100 µl of 0.4%
trypan blue in PBS (1:2 dilution). The number of live and or dead cells was determined by
adding 10μl to a hemocytometer and performing cell counts at 10x objective using a Nikon
Eclipse E600 Microscope. The average number of live cells per well was determined using the
equation: average number of live cells per corner square x 104 x 0.4 (total volume (ml) of cell
suspension from both wells) = number of cells per 100 µl of suspension. The same equation was
used to calculate the number of dead cells; percentage of live versus dead cells was then
determined.
TMRE Assay to Measure Mitochondrial Function
C6 cells were cultured as previously described. TMRE (BioTium) was used to determine
the mitochondrial membrane potential in C6 cells incubated with α-Syn for four days. The cells
were grown in T25 flasks to 100% confluency (three days). After reaching confluency, cells
were then incubated in a 1X Trypsin-EDTA solution (ATCC) and at 37⁰C until completely
38

detached. Following detachment, cells were resuspended in culture medium to a density of
40,000 cells/ml. Cells were plated into 96-well plates by adding 100 µl of cell suspension into
each well (4,000 cells/well). Overnight incubation was used to ensure cells were adhered to the
plate surface before replacing the medium in wells with medium containing various
concentrations of α-Syn. Cells were treated in duplicate at the following concentrations α-Syn: 0
µg/ml (control), 2 µg/ml, 4 µg/ml, 8 µg/ml, 16 µg/ml, 32 µg/ml, and 64 µg/ml. Following four
days of incubation with exogenous WT α-Syn, 5 µl of TMRE (500 nM stock solution) was added
to each well. A low concentration of TMRE was used to prevent aggregation and quenching of
the dye in the mitochondria (Perry et al., 2011). Additionally, 2.5 µl of Hoechst solution (1mg/ml
stock) was added to each well to provide a nuclear counterstain. Following addition of TMRE
and Hoechst, cells were incubated for at least 30 minutes at 37⁰C protected from light.
MetaMorph software along with a Nikon Eclipse TE2000-U inverted microscope using a 10X
objective lens was used to image cells. One field was imaged per well using both Texas Red and
DAPI filters (two images per treated or untreated group); each field was chosen using the DAPI
filter to ensure no bias in selecting the area. The same exposure times were used for all images
taken using the Texas Red filter; the same exposures were also applied to DAPI images. TMRE
staining was quantitatively analyzed using Fiji software (nih.gov). Two images were used from
each treatment group; these images were calibrated to 0.3444 μm/pixel. Each picture taken using
the Texas Red filter, was converted to 16-bit image. Background was then subtracted using
rolling ball background subtraction with sliding paraboloid (rolling ball radius=100 pixels). Two
equal sized regions of interest (ROI) were selected per image; to prevent bias, ROIs were placed
in the same location on each image. The Li thresholding algorithm was applied to each ROI to
select fluorescent mitochondria. The area and intensity of the fluorescent stained area was then
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measured; the raw integrated density was normalized to the area to determine the mean gray
value (the value of all pixels in the selected area normalized to the number of pixels). As a result,
the average fluorescent intensity of the selected mitochondria was determined for each ROI.
Since TMRE accumulates in active mitochondria due to their negative charge; depolarized or
less active (more positive) mitochondria will exhibit lower fluorescence (Perry et al., 2011).
Detection of Nuclear Morphology Changes
Images of C6 cells incubated with TMRE and Hoechst were captured as described
previously. Images taken using the DAPI filter were analyzed using Fiji software (nih.gov) and
calibrated to 0.3444 μm/pixel. Image files were opened in Fiji converted to 16-bit images and
smoothed. The threshold for each image was defined using the Otsu thresholding algorithm. In
order to detect nuclei and measure nuclear size, the particle analyzer was used to detect objects
ranging in size from 23.72 to 415.14 µm2 and with a circularity ranging from 0.75 to 1.00.
Statistical Tests
Statistical tests were run using SPSS software. A p-value of p≤ 0.05 was considered
statistically significant for statistical test. A One-Way ANOVA followed by a Tukey’s post hoc
test were used to detect differences in the dehydrogenase activity between untreated C6 cells and
cells incubated with exogenous WT α-Syn for both two and four days. A Kruskal-Wallis test was
used to determine differences in percent cell viability between untreated C6 cells and cells
treated with exogenous WT α-Syn for both two days and four days. A Welch’s test was used to
determine a difference in total cell numbers between untreated cells and cells incubated with
exogenous WT α-Syn for two days and four days.
A Kruskal-Wallis followed by a Mann-Whitney U post hoc test was used to determine if
differences in mitochondrial membrane potential occurred between cells incubated with
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exogenous WT α-Syn for four days normalized against untreated cells. A One-Way ANOVA
followed by a Tukey’s post hoc test was used to determine difference in nuclear size between
untreated C6 cells and cells incubated with exogenous WT α-Syn for four days.
Results
Decreases in Dehydrogenase Activity in C6 Cells Treated with α-Syn
To detect if α-Syn causes changes in the dehydrogenase activity of C6 cells associated
with metabolic dysfunction, cells were incubated with exogenous WT α-Syn for either two or
four days. Spectrophotometrical analysis showed a significant difference between untreated cells
and cells incubated with α-Syn for two days (p = 0.04) (Figure 7). Cells treated with 64 µg/ml of
α-Syn for two days exhibited a significant decrease in dehydrogenase activity when compared to
controls (p = 0.036). No significance was detected between any other groups (p ≥ 0.05). A
significant difference was detected between untreated cells and cells incubated with α-Syn for
four days (p = 3.19E-07) (Figure 8). After four days, analysis showed that cells incubated with 2,
4, 8, 16, 32, and 64 µg/ml of α-Syn exhibited a significant decrease in dehydrogenase activity
when compared to controls (p = 7.15E-05, 6.44E-07, 5.87E-06, 4.20E-05, 5.58E-06, 1.53E-06),
respectively. No statistical significance was detected between any other groups (p ≥ 0.05).
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Figure 7. Dehydrogenase Activity in C6 Cells Treated with α-Syn for Two Days. Data are represented as the mean
± SEM. A One-Way ANOVA followed by a Tukey’s post hoc test demonstrates that dehydrogenase activity in
untreated cells (0 µg/ml α-Syn) was significantly higher than cells treated with 64 µg/ml of α-Syn (n = 6, p ≤ 0.05).
*Significantly (p ≤ 0.05) different from control (untreated cells).
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Figure 8. Dehydrogenase Activity in C6 Cells Treated with α-Syn for Four Days. Data are represented as the mean
± SEM. A One-Way ANOVA followed by a Tukey’s post hoc test demonstrates that dehydrogenase activity in
untreated cells (0 µg/ml α-Syn) was significantly higher than cells treated with 2, 4, 8, 16, 32, and 64µg/ml of α-Syn
(n = 6, p ≤ 0.05). *Significantly (p ≤ 0.05) different from control (untreated cells).

Alpha-Synuclein Causes Changes in Cell Number but Not Cell Viability
Cell counts were performed with trypan blue to determine cell viability following both 2day and 4-day incubations with exogenous WT α-Syn. After evaluating dehydrogenase activity
using CCK-8 assay, live and dead cells were counted using a hemocytometer at 10x objective
using a Nikon Eclipse E600 Microscope. The percentage of viable cells in α-Syn treated groups
was not significantly different in either the 2-day incubation (p = 0.455) (Figure 9) or the 4-day
incubation (p = 0.612) (Figure 10) when compared to controls. The total cell numbers between
untreated cells and cells incubated with WT α-Syn for two days was not significantly different (p
= 0.118) (Figure 11). However, total cell numbers between untreated cells and cells incubated
with WT α-Syn for four days was significantly different (p = 2.39E-08) (Figure 12). Significantly
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more cells were observed in untreated cells when compared to cells treated with 32 and 64 µg/ml
α-Syn (p = 1.16E-04 and 3.14E-05), respectively. The total cell number in cells treated with 2
µg/ml α-Syn cells was significantly higher than cells treated with 16, 32, and 64 µg/ml of α-Syn
(p = 0.029, 1.78E-05, 5.26E-06), respectively. Similarly, significantly more cells were observed
in cells treated with 4 µg/ml α-Syn cells than cells treated with 16, 32, and 64 µg/ml of α-Syn (p
= 0.039, 1.91E-05, 5.59E-06), respectively. Cells treated with 8 µg/ml α-Syn also exhibited a
significantly higher cell number than cells treated with 64 µg/ml α-Syn (p = 0.038). No statistical
differences were detected between any other groups (p ≥ 0.05).
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Figure 9. Percent Viability in C6 Cells Treated with α-Syn for Two Days. Data are represented as the mean ± SEM.
Kruskal-Wallis test revealed no significant difference in cell viability between untreated cells (0 µg/ml α-Syn) and
cells treated with α-Syn for two days (n = 6, p ≥ 0.05).
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Figure 10. Percent Viability in C6 Cells Treated with α-Syn for Four Days. Data are represented as the mean ±
SEM. Kruskal-Wallis test revealed no significant difference in cell viability between untreated cells (0 µg/ml α-Syn)
and cells treated with α-Syn for four days (n = 6, p ≥ 0.05).
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Figure 11. Total Cell Numbers in C6 Cells Treated with α-Syn for Two Days. Data are represented as the mean ±
SEM. A Welch’s test showed that no significant difference in live cell number was detected between untreated cells
(0 µg/ml α-Syn) and cells treated with α-Syn for two days (n = 6, p ≥ 0.05).
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Figure 12. Total Cell Numbers in C6 Cells Treated with α-Syn for Four Days. Data are represented as the mean ±
SEM. A Welch’s test followed by a Games-Howell post hoc test reveals significantly higher cell counts in live
untreated cells (0 µg/ml α-Syn) compared to cells treated with 32 and 64 µg/ml α-Syn for four days (n = 6).
*Significantly (p ≤ 0.05) different from control (untreated cells).
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Changes in Mitochondrial Membrane Potential in C6 Cells Treated with α-Syn
TMRE was used to determine if mitochondrial function in C6 cells is affected following a
4-day incubation with exogenous WT α-Syn (Figure 13). TMRE is a fluorescent dye that
accumulates in active mitochondria, but not depolarized or inactive mitochondria. Image analysis
shows that the fluorescent intensity of TMRE, indicative of mitochondrial membrane potential,
was significantly different in cells incubated with of α-Syn when compared to controls (p =
0.006) (Figure 14). The mitochondrial membrane potential in untreated cells was significantly
higher than cells treated with 2, 32, and 64 µg/ml of α-Syn (p = 0.043, 0.021, and 0.021),
respectively. Cells treated with the highest dose of α-Syn (64 µg/ml), not only had a
mitochondrial membrane potential that was significantly lower than untreated cells but also
lower compared to cells treated with 4, 8, 16, and 32 µg/ml of α-Syn (p = 0.021, 0.043, 0.043,
0.043), respectively. Cells treated with 32 µg/ml of α-Syn exhibited a lower mitochondrial
membrane potential compared to cells treated with 4 µg/ml (p=0.021). Additionally, cells treated
with 2 µg/ml of α-Syn not only showed significantly lower mitochondrial membrane potential
than untreated cells but also lower mitochondrial membrane potential compared to cells treated
with 4 and 8 µg/ml of α-Syn (p = 0.021 and 0.043), respectively. No statistical differences were
detected between any other groups (p ≥ 0.05).
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Figure 13. TMRE Fluorescent Labeling in C6 Cells Treated with α-Syn for Four Days. Mitochondrial membrane
potential detected using TMRE in untreated cells, cells treated with exogenous WT α-Syn, and cells treated with
FCCP (mitochondrial oxidative phosphorylation uncoupler). Images were taken using 10X objective lens (scale
bar=25µm).
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Figure 14. Mitochondrial Membrane Potential in C6 Cells Treated with α-Syn for Four Days. Data are represented
as the mean ± SEM. Kruskal-Wallis followed by a Mann-Whitney U post hoc test demonstrates that the membrane
potential of mitochondria in untreated cells was significantly higher than cells treated with 2, 32, and 64 µg/ml of αSyn (n = 4, p ≤ 0.05). *Significantly (p ≤ 0.05) different from control (untreated cells) (a.u.= arbitrary units).

Alpha-Synuclein Leads to Nuclear Morphology Changes in C6 Cells
To detect changes in nuclear morphology of C6 cells treated with exogenous WT α-Syn,
nuclei were stained with Hoechst (Figure 15), and nuclear size was evaluated using image
analysis. Cells were treated with α-Syn for four days as previously described. Image analysis
showed that nuclear size in C6 cells was significantly different after a 2-day incubation with αSyn (p = 8.41E-06) (Figure 16). Nuclear size was significantly larger in cells treated with 32
µg/ml of α-Syn compared to untreated cells and cells treated with 2, 4, and 8 µg/ml of α-Syn (p =
0.002, 0.001, 0.001, and 4.98E-04), respectively. Results also show cells treated with 64 µg/ml
of α-Syn had a significantly larger nuclear size than untreated cells and cells treated with 2, 4,
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and 8 µg/ml of α-Syn (p = 0.002, 0.002, 0.001, and 0.001), respectively. Nuclear size in cells
treated with 16µg/ml are significantly larger than cells treated with 4 and 8 µg/ml of α-Syn (p =
0.032 and 0.032), respectively. No statistical differences were detected between any other groups
(p ≥ 0.05).
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Figure 15. Changes in Nuclear Morphology in C6 Cells Treated with α-Syn. Nuclei stained with Hoechst in
untreated cells and cells treated with exogenous WT α-Syn. Images were taken using 10X objective lens (scale
bar=25µm). Images were converted to 16-bit gray scale and overlaid with cyan for visualization.
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Figure 16. Nuclear Size in C6 Cells Treated with α-Syn for Four Days. Data are represented as the mean ± SEM. A
One-Way ANOVA followed by a Tukey’s post hoc test revealed significantly larger nuclei in cells treated with 32
and 64 µg/ml (n = 4, p ≤ 0.05). *Significantly (p ≤ 0.05) different from control (untreated cells).

Discussion
The primary pathological feature of MSA is the accumulation of misfolded α-Syn in
oligodendrocytes, forming α-Syn containing GCIs (Burn and Jaros, 2001; Trojanowski and
Revesz, 2007). Interesting, α-Syn is a neuronal protein and is either not expressed, or expressed
to a negligible degree in mature human oligodendrocytes (Miller et al., 2005; Reyes et al., 2014).
Therefore, current studies suggest that oligodendroglia pathology in MSA is promoted by the
accumulation of exogenous α-Syn rather than increased expression in oligodendrocytes (Miller et
al., 2005; Reyes et al., 2014). In addition to the formation of inclusions in oligodendroglia, α-Syn
causes pathological changes in astrocytes including gliosis and the production of
neuroinflammatory molecules (Lee et al., 2010a; Lee et al., 2010b; Vieira et al., 2015). To
replicate the cellular pathology that occurs in the MSA brain, this study describes a cell culture
model using C6 rat glioma cells incubated with exogenous WT α-Syn. This research suggests
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that C6 cells incubated with WT α-Syn exhibit mitochondrial dysfunction and nuclear
morphology changes, without significant changes in cell viability.
Rat derived C6 glioma cells can exhibit both oligodendrocytic and astrocytic phenotypes
(Coyle, 1995), allowing for a cell culture model which displays characteristics of two glia
subtypes affected by α-Syn in MSA. While α-Syn can be taken up by neuronal cells though cell
to cell contact (Desplats et al., 2009), it has also been shown to be taken up from culture medium
in both neurons and glial cells (Desplats et al., 2009; Lee et al., 2008). A study by Valera et al.
and previous work in our lab (Hilton, 2012) indicate that C6 cells are capable of internalizing αSyn from culture medium (Hilton, 2012; Valera et al., 2014). While the expression of multiple
glial characteristics by C6 glioma cells is advantageous in this study, it is important to note that
these cells lack contact inhibition. Cultures need to be carefully maintained to prevent cells from
continuing to proliferate upon reaching a hundred percent confluency. The use of C6 glioma
cells allows for a model to evaluate the direct effect of α-Syn on isolated glial cells,
demonstrating that pathology occurs even in the absence of other cell interactions. However, the
use of one cell type limits the ability to examine the complex communication that occur between
various cell types and how α-Syn impacts these relationships; this includes the interaction
between immune cells, neurons, and glial cells. Additional studies incorporating co-cultures of
different cell types (e.g. neuronal and glial cells) may allow for a more complete understanding
of how α-Syn impacts different cells types and how these effects are related.
Previous Affymetrix data in the Ide lab demonstrated the down regulation of multiple
genes involved in mitochondrial function and metabolism in MSA pons tissue (Langerveld et al.,
2007). Consistent with these findings, multiple studies suggest that alpha-synuclein may induce
mitochondria dysfunction (Parihar et al., 2008; Li et al., 2003; Shavali et al., 2008; Hsu et al.,
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2000; Martin et al., 2006). In this study, potential metabolic changes were investigated by
measuring dehydrogenase activity. WST-8 is typically used to determine cell viability through
reduction of the dye by dehydrogenase activity (Berridge et al., 2005; Ishiyama et al., 1997;
Tominaga et al., 1999). Higher levels of dehydrogenase activity in healthy cells, reduces WST-8
to an orange formazan dye that is soluble in the culture medium (Berridge et al., 2005; Ishiyama
et al., 1997; Tominaga et al., 1999). However, the color change of tetrazolium salts, including
WST-8, may more directly correlate with metabolic activity of cells rather than viability and can
provide measurement of NADH and NADPH (Berridge et al., 2005; Menyhárt et al., 2016).
WST-1, a tetrazolium salt reduced similarly to WST-8, is reduced extracellularly via an electron
mediator, 1-methoxy-5-methyl-phenazinium methyl sulfate (mPMS), which interacts with
NADH and NADPH at the plasma membrane (Berridge et al., 2005). The source of NADH is
thought to come primarily from the mitochondrial citric acid cycle (Berridge et al., 2005). It is
also thought that superoxide, precursor to other reactive oxygen species (ROS), may indirectly
play a role in WST-8 reduction (Berridge et al., 2005). In this study, a significant decrease in
dehydrogenase activity was observed in cells treated for two days with the high dose of α-Syn
(64 µg/ml) compared to untreated cells (controls). Statistical significance was not observed in
any other dose, indicating that dehydrogenase activity is affected in a dose dependent manner. As
for cells treated for four days with exogenous α-Syn, all treated groups exhibited a significant
decrease in dehydrogenase activity compared to controls. Since no statistical differences were
detected between any other groups, this indicates that the 4-day incubation α-Syn was sufficient
to induce metabolic dysfunction at all concentrations, ranging from low (2 µg/ml) to high (64
µg/ml). Since the reduction of WST-8 dye is dependent on NADH concentrations, decreases in
dehydrogenase activity indicate reduced levels of NADH. This may suggest dysfunction along
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the electron transport chain since NADH produced during the citric acid cycle is then utilized in
oxidative phosphorylation. These data suggest that treatment of C6 cells with exogenous α-Syn
negatively affects cellular respiration, inducing metabolic/mitochondrial dysfunction potentially
related to oxidative stress.
Since WST-8 dye is an indicator of dehydrogenase activity but not necessarily cell
viability, it is necessary to further examine the effect of α-Syn on cell death. In astrocytoma cells
overexpressing α-Syn, poor cell attachment has been observed accompanied by increased
apoptosis and susceptibility to oxidative stress (Stefanova et al., 2001). Consistent with the study
by Stefanova et al. (Stefanova et al., 2001), observations from the current study found that cells
treated with α-Syn did not adhere as strongly as untreated cells to the wells of the 96-well plates.
Poor cell attachment could indicate a cytotoxic response (Stefanova et al., 2001). To evaluate
cytotoxicity, trypan blue staining was used to determine if exogenous α-Syn induces changes in
C6 cell viability following incubation with exogenous α-Syn. No statistical significance in cell
viability was found between untreated cells and cells incubated with α-Syn for either two or four
days. However, it is important to note that in the 4-day treatment, 4 out of 6 plates demonstrated
that cells incubated with 64 µg/ml of α-Syn exhibit a slight decrease in cell viability compared to
controls. Trypan blue is a vital stain taken up by non-viable cells due to a loss of membrane
integrity; it does not distinguish between apoptosis and necrosis (Louis and Siegel, 2011). It is
possible that cells may be experiencing the earlier stages of apoptosis, which may not be
detectable via trypan blue staining. To better characterize the effect of α-Syn on viability in C6
cells, additional studies should involve differentiation between apoptotic (early or intermediate
stages) and necrotic cells. It is also possible that additional interactions are necessary to induce
significant cell death. As mentioned in chapter 2, a greater number of CD8 positive lymphocytes
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were detected in MSA brain tissue. Activated CD8+ T cells may target glial cells affected by αSyn and lead to cell death through the induction of apoptosis.
While changes in percent viability were non-significant between untreated and treated
cells, a reduction in total cell number was significantly different in the 4-day treatment and
followed a dose dependent trend. A decrease in cell number has been previously observed in
neuronal cells treated with α-Syn oligomers (Danzer et al., 2007). It is possible that the low cell
number is due to necrosis or autophagy; however, a decrease in proliferation is another potential
cause. A study by Flierl et al., suggests that neuronal cells expressing triplication of the SNCA
gene exhibit a decline in proliferation (Flierl et al., 2014). Further studies on proliferation rate in
α-Syn treated cells are necessary for understanding how cell growth is impacted by exogenous αSyn.
While results of the CCK-8 assay suggests metabolic distress in cells treated with α-Syn,
it does not directly measure mitochondrial function. Mitochondria are large producers of ATP
and crucial for regulation of cellular energy. It is therefore necessary to determine if α-Syn
negatively impacts these critical organelles. Maintenance of mitochondrial membrane potential
(electrical potential) is essential for regulating the electron transport chain and production of
ATP (Perry et al., 2011). Thus, the mitochondrial membrane potential was evaluated to
determine a direct effect of α-Syn on mitochondrial function.
The suspicion that α-Syn is associated with mitochondrial dysfunction is supported by
previous literature, in which the overexpression of α-Syn in neuronal cells has been shown to
induce decreases in mitochondrial membrane potential (Parihar et al., 2009). It has also been
described that changes in membrane potential are accompanied by an increase in ROS in cells
treated with exogenous α-Syn (Reeve et al., 2015) and cells overexpressing α-Syn (Parihar et al.,
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2009). Additional evidence points to deficits in mitochondrial function in MSA, by the discovery
of mutations in the COQ2 gene in MSA patients within a Japanese population (Multiple-System
Atrophy Research Collaboration, 2013). Reduced function of COQ2 impacts the function of
Coenzyme Q10, suggesting dysfunction in the mitochondrial respiratory chain (Multiple-System
Atrophy Research Collaboration, 2013).
This study demonstrates changes in mitochondrial membrane potential in C6 cells after a
4-day incubation with α-Syn. Cells treated with the highest concentration of α-Syn (64 µg/ml)
showed a reduced mitochondrial membrane potential when compared to untreated cells and cells
treated with 4, 8, 16, and 32 µg/ml. Since mitochondrial membrane potential is an indicator of
mitochondrial function, this work suggests that incubation of C6 cells with exogenous WT α-Syn
induces a reduction in mitochondrial function. Interestingly, cells treated with the lowest
concentration of α-Syn (2 µg/ml) exhibited a significantly lower mitochondrial membrane
potential compared to untreated cells and cells treated with 4 and 8 µg/ml of α-Syn. This effect
may indicate that cells treated with mid-range concentrations are attempting to compensate for
mitochondrial dysfunction by increasing activity along the mitochondrial respiratory chain.
These data suggest that α-Syn can induce lowered mitochondrial function in C6 cells.
Interestingly, in addition to maintaining the electron transport chain and production of ATP,
mitochondrial membrane potential is also involved in apoptotic signaling. In fact, decreased
mitochondrial membrane potential is associated with early apoptosis (Ly et al., 2003). It is
thought that some loss of the mitochondrial membrane potential occurs by an unidentified
stimulus before caspase activation, which is then followed by release of cytochrome c and
activation of caspases (Ly et al., 2003). It is possible that C6 cells may be going through early
stages of apoptosis that are not easily detectable. Another potential cause for reduced
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mitochondrial membrane potential is the increase of ROS in response to α-Syn accumulation in
C6 cells. Since previous observations suggest that overexpression of WT α-Syn can promote
ROS in dopaminergic cells (Junn and Mouradian, 2002), it is suspected that α-Syn could induce
greater ROS production in C6 cells. Increases in ROS can negatively affect the mitochondrial
membrane potential, since production of ROS is associated with depolarization of mitochondria
(Zorov et al., 2014).
Alpha-synuclein containing GCIs are found near or surrounding the nucleus within
oligodendrocytes in MSA (Ahmed et al., 2012; Burn and Jaros, 2001; Trojanowski and Revesz,
2007). Oligodendrocytes containing GCIs often exhibit enlarged nuclei compared to non-GCI
containing cells (Ahmed et al., 2012). Changes in nuclear morphology were detected in C6 cells
following a 4-day incubation with α-Syn, revealing a dose dependent trend. Nuclei in cells
treated with the two highest concentrations of α-Syn (32 and 64 µg/ml) were substantially larger
than untreated cells and cells treated with 2, 4, and 8 µg/ml α-Syn. Additionally, nuclei in cells
treated with 16 µg/ml were larger than cells treated with 4 and 8 µg/ml of α-Syn. The appearance
of enlarged nuclei in cells treated with high concentrations of α-Syn may indicate the formation
nuclear inclusions. It is possible that cells treated with lower concentrations of α-Syn have not
accumulated substantial amounts of α-Syn to cause swelling of the nucleus.
While the cell culture model in this study demonstrates the early effect of α-Syn on C6
glioma cells, additional work is needed to evaluate the long-term effects of α-Syn on glial cell
function and viability. Future studies should include longer incubations with α-Syn, to determine
if certain effects remain consistent, amplify, or decrease over time. As mentioned previously, the
results from this study indicate that total cell number decreased with increasing concentrations of
α-Syn without impacting cell viability. Additional research is needed to determine if α-Syn is
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inhibiting proliferation and or if cells are at early stages of apoptosis that are not detectable using
trypan blue. Future analyses, potentially using in vivo studies or co-cultures, are needed to
determine interactions between immune cells and glial cells in the presence of aggregated α-Syn.
Conclusion
In conclusion, this work developed a cell culture model of MSA using C6 glioma cells in
the presence of exogenous WT α-Syn. The addition of α-Syn directly into cell cultures is thought
to mimic the uptake of α-Syn by oligodendrocytes as it occurs in MSA. These data demonstrated
decreases in dehydrogenase activity in C6 cells treated with exogenous α-Syn, indicating some
degree of metabolic dysfunction. Remarkably, cell viability was not impacted by treatment with
α-Syn. This suggests that reduction in metabolic function can occur without a significant amount
of cell death. Decreases in cell number may indicate that treatment with α-Syn leads to inhibition
of proliferation in C6 cells. In support of lower dehydrogenase levels, C6 cells treated with αSyn exhibited lower mitochondrial membrane potential suggesting a direct effect on
mitochondria resulting in decreased function. Changes in cell morphology were also detected, as
cells treated with α-Syn experience dose-dependent increases in nuclear size, potentially due to
accumulation of α-Syn in or surrounding the nucleus. It is evident that the highest concentrations
of α-Syn produced the greatest overall effect, leading to significant decreases in dehydrogenase
activity, mitochondrial function, and cell number, accompanied by significant changes in nuclear
morphology.
From results obtained in this study, it can be concluded that both an innate and adaptive
immune response play a role in the progression of MSA. Increases in immune proteins were
detected in the pontocerebellar tracts, an area previously shown to have increased expression of
aggregated α-Syn (Langerveld et al., 2007), the protein thought to cause primary neuropathology
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in MSA. While α-Syn is thought to be associated with an increased immune response, the
hallmark of MSA is the accumulation of α-Syn in oligodendrocytes (Burn and Jaros, 2001;
Trojanowski and Revesz, 2007). The results of this research suggest that in addition to increases
in immune cells, α-Syn directly leads to various glial cell pathologies as observed in the C6
glioma cell culture model used in this study. These pathologies included decreases in
metabolic/mitochondrial function and visible changes in nuclear morphology. It is likely that a
combination of reactive immune cell activity plus cellular dysfunction in oligodendrocytes and
astrocytes results in the pathogenesis of MSA.
As previously discussed, future work is needed to define the role the innate and adaptive
immune proteins identified in this study and the specific interaction with α-Syn, such as
colocalization studies between these immune proteins and α-Syn. Further work is also needed to
define the specific effect of α-Syn on glial cells, such as a longer duration of α-Syn treatment,
and additional assays to evaluate proliferation and potential apoptosis.
This research makes a valuable contribution to MSA research by better defining the
immune response in an area of the MSA brain affected by α-Syn. Additionally, a cell culture
model of MSA was developed to determine the effect of α-Syn on glial cells. Therefore, this
work not only identified an immune response but describes a cell culture model that can be used
to pinpoint specific areas of cellular dysfunction and to test potential drugs and therapeutics that
may be beneficial in treating MSA.
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